Psychedelic medicine proponents are redirecting their efforts to use millions in opioid-related state settlement money for ibogaine research from Kentucky to Ohio.
The original plan to use $42 million from Kentucky’s opioid settlement fund for psychedelics research fell through late last year after the state’s new attorney general replaced then-Kentucky Opioid Commission Chairman Bryan Hubbard, who was spearheading the ibogaine initiative, with a former Drug Enforcement Administration (DEA) official.
Now Hubbard has joined ResultsOHIO, a division of the Ohio Treasurer’s Office, where he will be partnering with the Reaching Everyone in Distress (REID) Foundation in hopes of securing a portion of that state’s opioid settlement funds to promote psychedelics clinical trials for substance misuse treatment.
“I’m honored to work with the REID Foundation and the people of Ohio to bring hope and healing to veterans and families being torn apart by the opioid crisis,” Hubbard said in a press release. “The development of ibogaine as a treatment option for opioid-dependent individuals is a moral imperative.”
A Kentucky commission focused on opioid overdose abatement held several meetings last year to go over the ibogaine initiative that’s since fizzled out in that state under the new attorney general. Members heard testimony from
Read full article on Marijuana Moment
